Blood biomarkers may reveal hidden heart rhythm risk

NCT ID NCT02808260

Recruiting now Knowledge-focused Sponsor: Ottawa Heart Institute Research Corporation Source: ClinicalTrials.gov ↗

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This study investigates whether certain proteins or chemical changes in the blood can predict who will develop atrial fibrillation (AF), a condition that can lead to strokes. Researchers will follow 500 people with implanted pacemakers or defibrillators for up to 11 years, using the devices to detect early, symptom-free episodes of irregular heartbeats. The goal is to find biomarkers that could allow earlier treatment and possibly prevent AF from becoming permanent.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors identify people at risk for atrial fibrillation early, potentially preventing strokes and permanent heart rhythm problems.
What could go wrong: This is an observational study, not a treatment trial. It may not find reliable biomarkers, and any findings would need further testing before they could be used in practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATRIAL FIBRILLATION

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

University of Ottawa Heart Institute
RECRUITING

Ottawa, Ontario, K1Y 4W7, Canada

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.